Oct. 25 at 6:38 PM
$BRQSF A compelling case against the narrative that the
$30 million Sasken upfront was just a wash due to the
$29 million liabilities from the 2024 20-F:
There was no cash drain post-HHE sale. It showed
$15M net gain and cash equivalents increased to
$2 million and reducing liabilities by
$6.9 million
Similarly, the projected H1 2025 financials (based on
$7-10 million Q1 revenue and
$30M Sasken payment) should show a net gain of
$27.5 -
$32 million for 2025. Should reduce liabilities by
$17-20 million, and boost cash reserves to
$5-10 million.
Then the anticipated
$10 million earn-out payment will further increase cash holdings, enhancing Pat Chan’s pivot potential. My hopenis he pivots and we see the .50-
$1.00 range in 2026